Journal
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Volume 125, Issue -, Pages 97-102Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2022.09.033
Keywords
Urinary tract infection; Extended-spectrum; beta-lactamase-producing; Enterobacteriaceae; Cephalosporins
Categories
Ask authors/readers for more resources
This study aimed to clarify the risk factors and treatment strategies for febrile urinary tract infection (fUTI) caused by ESBL-producing bacteria in Japanese children. The results showed that children with a history of recent antibiotic use or prophylactic antibiotic use and recurrent UTIs were more likely to have fUTI caused by ESBL-producing bacteria. Regardless of the choice of antibiotic, most children with fUTI experienced clinical improvement.
Objectives: The incidence of infections caused by extended-spectrum beta-lactamase (ESBL)-producing bacteria has increased. This study aimed to clarify the risk factors and treatment strategies for febrile urinary tract infection (fUTI) caused by ESBL-producing bacteria in Japanese children. Methods: A retrospective observational study was conducted in 21 hospitals among children aged < 16 years diagnosed with an fUTI between 2008 and 2017. Clinical data of children with fUTI caused by ESBL-producing and non-ESBL-producing bacteria were compared. Results: Of the 2049 cases of fUTI, 147 (7.2%) were caused by ESBL-producing bacteria. Children in the ESBL group were more likely to have a history of recent antibiotic use or prophylactic antibiotic use, and experience recurrent UTIs ( P < 0.001) compared with those in the non-ESBL group. Of the 124 cases of fUTI due to ESBL-producing bacteria that were reviewed, 20 and 100 had concordant and discordant antibiotic use, respectively, and four had unknown antibiotic susceptibility. The median time from the start of treatment to fever resolution was 24 hours and did not differ significantly by therapy group ( P = 0.39). Conclusion: ESBL-producing bacteria should be considered in children with recurrent UTIs and recent antibiotic use. Most children with fUTI experience clinical improvement regardless of the choice of an-tibiotic. & COPY; 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available